Saline Injection
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasciitis, Plantar
Conditions
Fasciitis, Plantar
Trial Timeline
Mar 31, 2015 → Aug 1, 2018
NCT ID
NCT02427191About Saline Injection
Saline Injection is a phase 2/3 stage product being developed by MiMedx Group for Fasciitis, Plantar. The current trial status is completed. This product is registered under clinical trial identifier NCT02427191. Target conditions include Fasciitis, Plantar.
What happened to similar drugs?
0 of 1 similar drugs in Fasciitis, Plantar were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
15
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03414268 | Phase 3 | Completed |
| NCT02427191 | Phase 2/3 | Completed |
Competing Products
3 competing products in Fasciitis, Plantar
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin 6mg/kg/day | Merck | Pre-clinical | 26 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 2/3 | 35 |
| Saline Injection | MiMedx Group | Phase 3 | 34 |